Based in Mauritius, Centre International de Développement Pharmaceutique (CIDP) is a private and independent Contract Research Organisation (CRO) that conducts cosmetics research and clinical activities.
1. What are consumers’ key demands and considerations when opting for anti-pollution items?
Consumers look for the visual demonstration of effectiveness supported by objective measurements.
A product with an anti-pollution claim should either prevent pollutants from adhering to the skin surface, remove pollutants from the skin, or in reduce the detrimental impact of pollutants while simultaneously regenerating the skin.
At the end of the day, consumers want to be assured that the product being used prevents their skin from deteriorating, and proving this efficacy will satisfy them.
2. How is CIDP helping to transform the industry?
CIDP is an independent CRO that offers the personal care industry a full suite of services – comprising research activities, in vitro and ex vivo testing, analytical chemistry, formulation, and clinical research.
Possessing an innovative spirit, CIDP is not just a supplier, but a trusted partner that delivers consistent and effective results in an efficient manner. We endeavor to be one step ahead of our customers, by anticipating their needs and demands.
Across our five ISO-certified centres across the globe, CIDP offers cosmetics manufacturers objective means to claims substantiation, through the development of new methodologies that address the industry’s needs.
3. What is CIDP’s USP?
Compared to other service providers on the market, CIDP’s protocols and models take on a more holistic approach, comprising biochemical and biophysical evaluations.
4. What has been CIDP’s standout moment to date?
Our standout moment will always be tomorrow.
We will not stop researching and proposing new protocols and innovations to our clients. In fact, we are also working on new ingredients sourced in the Indian Ocean, and we already have some requests from clients.
The cosmetics and personal care markets are constantly evolving, especially so when it comes to innovation, and CIDP wants to remain and be positioned as ‘the innovative CRO’.
“CIDP aims to be the ideal partner to cosmetic manufacturers for their research needs,” stated Mr Jean-Louis Roule, CEO of CIDP.
“Our anti-pollution and blue light protocols had been well-received in Europe...The United States is an important market for CIDP, and we’re looking to build on our success in Europe, and strengthen our international strategy by establishing our presence here,” Roule added.
The second part of this article, which delves into CIDP’s new ex vivo model and anti-pollution and blue light study protocols, will be published on Wednesday 18th October.